Earnings ·
Reports Q3 revenue of €1.29 billion, raises full-year guidance to €1.7–1.9 billion
BNTXBioNTech SE
BioNTech reported third-quarter revenues of €1,289.2 million and a net profit of €184.5 million, driven by its partnership with Bristol Myers Squibb. The company raised its full-year 2026 revenue guidance midpoint to €1.7 billion from €1.6 billion, setting the range at €1.7–1.9 billion. Adjusted R&D expenses were €578.5 million and adjusted SG&A expenses were €178.5 million. BioNTech also announced it exercised an option in its collaboration with Roche/Genentech to shift future R&D costs for a specific program to the partner effective January 1, 2027. The company maintains a strong financial position with €16.2 billion in cash and investments. BioNTech is a global biopharmaceutical company pioneering mRNA-based therapies for cancer and infectious diseases.